FST.L Regulatory News (FST)

26 Feb 2007 07:00

Embargoed Release: 07:00hrs Monday 26th February 2007

Nanoscience Inc. (`Nanoscience' or the `Group') Key Development Milestone - Transition to Commercial Production

Nanoscience Inc., the specialist niche investor in emerging technologies with strong commercial propositions from within the growing nanotechnology sector, is pleased to announce that its wholly owned subsidiary, Toumaz Technology Limited (`Toumaz'), has successfully developed and tested the first fully integrated, single chip version, of its pioneering Sensium platform. As a result of this significant development, Toumaz will be making available for the first time its range of wireless remote patient monitoring applications to a range of customers in both the healthcare and pharmaceutical sectors from the beginning of March this year.

Since the Group's acquisition of Toumaz in November 2005, development of the patented Advanced Mixed Signal (`AMx') technology into an integrated chip has been critical for the commercialisation of the Sensium healthcare platform. The significance of this development milestone is that it facilitates the volume production of Toumaz's healthcare solution, thereby leading the way to significant cost reduction and supply in commercial volumes.

The Sensium platform provides a whole solution to cover the last metre of bio-data communication and connects the mobile patient via any network to his or her healthcare provider. In addition, the directors of Nanoscience believe that the complete system of intelligent body worn wireless sensors and associated networking is delivered with significantly lower power consumption than any currently available alternative solution thereby enabling longer usage.

To date, Toumaz has been working extensively with more than 20 prospective customers in both the USA and Europe on various product functionality trials since the first Sensium non-integrated modules were produced in October of last year. As a consequence of the trialing process and deepening commercial interaction with potential customers, in January of this year Toumaz was selected by a Fortune 100 company for inclusion in its official supplier list.

Chris Toumazou, Director, Nanoscience, commented:

`The large organisations we are engaged with in a range of industry sectors view the integrated Sensium monitoring platform as a technological revolution that will provide them with a range of opportunities around which to build their own applications and services. With our integrated mobile patient monitoring platform we bring together 3 key components:

* Firstly, we can gather real-time processed information from raw data that is processed `on-chip' to intelligently extract key biosensor information thereby providing real-time feedback to patients whilst enabling healthcare providers to focus on the key issues and deliver care on a pre-emptive basis. * Secondly, our body worn sensors operate using our ultra-low power patented AMx technology. This technology, coupled with low power radio and intelligent information handling, results in an ultra-low power, body-worn solution, enabling non-intrusive, continuous monitoring. * Finally, our technology is now a complete end-to-end system providing the low power radio link from the patient to the telecommunications network and into the healthcare provider's database systems, offering new levels of reassurance and enabling new service delivery models. The data collected by our body worn Sensium chips is then filtered and processed by application software and integrated into existing medical information systems, such as those employing the worldwide HL7 standard. Accordingly, this completes the end-to-end solution and the backbone of a revolutionary total patient care package.

The integrated Sensium chip achieved all of its targeted accuracy and performance parameters in functional testing only 18 months after its initial specification, thereby signaling a breakthrough for a new generation of low-cost, disposable, lifestyle and healthcare solutions, which have been eagerly anticipated in the industry.'

Guy Spelman, CEO Nanoscience, commented:

`The performance of the Toumaz team is to be congratulated. The single chipSensium announced today is the first in a planned family of low power sensorinterface systems currently being developed. The product roadmap over the next18 months will deliver devices for the analysis of vital signs with even lowerpower consumption and greater algorithmic efficiency, enabling longer productlife spans at even lower cost. This is a key step in our programme ofcommercialisation. -Ends- Further information:Richard Rose Nanoscience 07836 250 474 Andrew Tan Hansard Group 020 7245 1100 www.hansardgroup.co.uk About Toumaz (www.toumaz.com)

Toumaz, the recent winner of the first prize at the fifth Oracle PartnerNetwork (OPN) Innovation Awards for Europe, the Middle East and Africa is a developer of advanced RF, analogue and mixed signal semiconductors. The focus of the business is low power devices based on the company's proprietary AMx¢â€ž¢ (Advanced Mixed Signal) technology which addresses the needs of lower power consumption for mobile and wirelessly connected systems.